Fmr LLC Increases Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

FMR LLC lifted its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 6.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 218,561 shares of the company's stock after buying an additional 12,327 shares during the quarter. FMR LLC owned about 0.37% of Twist Bioscience worth $9,875,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. grew its position in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience during the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Insider Activity

In related news, CAO Robert F. Werner sold 1,448 shares of the company's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company's stock, valued at approximately $2,034,652. This represents a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the transaction, the chief financial officer now directly owns 73,397 shares of the company's stock, valued at $3,068,728.57. The trade was a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock valued at $4,584,508 in the last quarter. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Stock Performance

TWST stock traded down $1.47 on Thursday, hitting $47.39. 781,236 shares of the company's stock were exchanged, compared to its average volume of 940,034. The firm has a 50 day moving average price of $44.76 and a two-hundred day moving average price of $46.59. The stock has a market cap of $2.81 billion, a P/E ratio of -13.57 and a beta of 1.82. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a report on Tuesday, November 19th. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. TD Cowen reiterated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.